Parallel distribution is the distribution of a centrally authorised medicinal product from one Member State to another, by a pharmaceutical company, independent of the marketing-authorisation holder.

Parallel distribution of pharmaceutical products is made possible by the existence of price differences between different national markets within the EEA enabling the sale of medicines at a more cost effective price than would have been previously possible.

The parallel import of medicinal products is based on the principle of free movement of goods between EU member states. Their legality has been recognised by the Court of Justice of the European Communities since 1976.

The advantages of parallel distribution are to reduce medicine shortage on the domestic market and bring quality products to the market at a lower price, resulting in substantial cost savings for health care providers, pharmacists and patients. With the NHS in the UK those savings directly benefit the government and the pharmacist.


Parallel importation and distribution throughout Europe is strictly regulated to evaluate and supervise medicines for the benefit of public health and to ensure patient safety.

Mediwin Ltd meets the precise conditions of the national parallel import regulatory authority, the Medicines & Healthcare products Regulatory Agency ( MHRA ) and the parallel distribution authority within the European Union, the European Medicines Agency ( EMA ).

Parallel importers and distributors are subject to the same regulatory requirements as the original manufacturers and undergo regular stringent controls by the relevant national and European regulatory authorities.

Mediwin Ltd are an active member of the British Association of European Pharmaceutical Distributors ( BAEPD ) and the European Association of Euro-Pharmaceutical Companies
EAEPC ) which represent Europe’s licensed parallel trade industry and actively promotes the achievements and benefits of its products across Europe.